title: MicroRNA therapeutics: the emerging anticancer strategies.
abstract: The genetic alterations and aberrant miRNA expression profiles have been identified as important events behind the emergence of cancer. This knowledge triggers the use of miRNA therapeutics as an anticancer strategy. Basically, MicroRNAs (miRNAs) are approximately 22-nucleotide long, endogenous non-protein-coding RNA molecules which function as important regulatory molecules that regulate gene and protein expression through the RNA interference (RNAi) machinery. Transcription of these molecules by RNA polymerases II and III, resulting in the generation of precursor microRNAs that undergo a series of cleavage events, consequently, generate the mature microRNA. The biogenesis pathway is mediated by the two important cleavage events such as nuclear and cytoplasmic. The regulatory functions of microRNAs are accomplished through the RNA-induced silencing complex (RISC), leading to translational repression and hence, regulate the gene expression. The current progress in the development of strategies for miRNA-based anticancer therapies is due to its involvement in cellular, developmental and biological processes including regulation in cancer cell and modulation by various cancer chemoprophylaxis agents. Although miRNA therapeutics have been found to suppress gene expression effectively as compared to anti-sense oligonucleotide strategies, but it is bound with some limitations viz. identification of tissue specific miRNA, biological instability, off-target effects and delivery in the cell system. Up to certain extent, these hurdles have been resolved by chemical modifications using cholesterol conjugation, morpholinos, cationic lipids and cationic nanoparticles. Still more research is needed to understand the mechanism of action for better miRNA therapeutics. The paper discusses the potential miRNA therapeutics and diagnostic applications for cancer prevention, based on recent patents and their analysis.
authors.forename: Chakresh K
authors.initials: CK
authors.lastname: Jain
authors.forename: Aman
authors.initials: A
authors.lastname: Gupta
authors.forename: Nidhi
authors.initials: N
authors.lastname: Dogra
authors.forename: Vipul S
authors.initials: VS
authors.lastname: Kumar
authors.forename: Gulshan
authors.initials: G
authors.lastname: Wadhwa
authors.affiliation: Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector-62, NOIDA, U.P. (India). ckj522@yahoo.com.
authors.forename: Sanjeev K
authors.initials: SK
authors.lastname: Sharma
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009857:Oncogenes / Q000235:genetics; D010330:Patents as Topic; D034622:RNA Interference
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs